[Ip-health] KEI Research Note 2020:1 Role of the U.S. Federal Government in the Development of GS-5734/Remdesivir
zrizvi at citizen.org
Sat Mar 21 10:03:57 PDT 2020
This is great. Thanks for doing this.
The NIH has also disclosed that its phase 2 trial will cost at least $30 million this fiscal year.
On Mar 21, 2020, at 12:53 PM, Claire Cassedy <claire.cassedy at keionline.org> wrote:
Kathryn Ardizzone has written a briefing note on U.S. federal support for
the development of GS-5734/Remdesivir.
KEI Research Note 2020:1 Role of the U.S. Federal Government in the Development
KEI Briefing Note 2020:1: Role of the U.S. Federal Government in the
Development of GS-5734/Remdesivir
Kathryn Ardizzone. March 20, 2020.
Ip-health mailing list
Ip-health at lists.keionline.org
More information about the Ip-health